These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37838556)

  • 61. Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans.
    Alberts AR; Schoots IG; Bokhorst LP; van Leenders GJ; Bangma CH; Roobol MJ
    Eur Urol; 2016 Jun; 69(6):1129-34. PubMed ID: 26651990
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Added value of randomised biopsy to multiparametric magnetic resonance imaging-targeted biopsy of the prostate in a contemporary cohort.
    Chaloupka M; Pyrgidis N; Ebner B; Volz Y; Pfitzinger PL; Berg E; Enzinger B; Atzler M; Ivanova T; Clevert DA; Buchner A; Stief CG; Apfelbeck M
    BJU Int; 2024 May; 133(5):548-554. PubMed ID: 38060339
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Detection of anterior prostate cancer using a magnetic resonance imaging-transrectal ultrasound fusion biopsy in cases with initial biopsy and history of systematic biopsies.
    Abe M; Takata R; Ikarashi D; Sekiguchi K; Tamura D; Maekawa S; Kato R; Kanehira M; Ujiie T; Obara W
    Prostate Int; 2023 Dec; 11(4):212-217. PubMed ID: 38196555
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Ipsilateral hemigland prostate biopsy may underestimate cancer burden in patients with unilateral mpMRI-visible lesions.
    Phelps TE; Yilmaz EC; Harmon SA; Belue MJ; Shih JH; Garcia C; Hazen LA; Toubaji A; Merino MJ; Gurram S; Choyke PL; Wood BJ; Pinto PA; Turkbey B
    Abdom Radiol (NY); 2023 Mar; 48(3):1079-1089. PubMed ID: 36526922
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Clinical implementation of pre-biopsy magnetic resonance imaging pathways for the diagnosis of prostate cancer.
    Israël B; Immerzeel J; van der Leest M; Hannink G; Zámecnik P; Bomers J; Schoots IG; van Basten JP; Debruyne F; van Oort I; Sedelaar M; Barentsz J
    BJU Int; 2022 Apr; 129(4):480-490. PubMed ID: 34358388
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The Utility of Combined Target and Systematic Prostate Biopsies in the Diagnosis of Clinically Significant Prostate Cancer Using Prostate Imaging Reporting and Data System Version 2 Based on Biparametric Magnetic Resonance Imaging.
    Kato D; Ozawa K; Takeuchi S; Kawase M; Kawase K; Nakai C; Takai M; Iinuma K; Nakane K; Kato H; Matsuo M; Suzui N; Miyazaki T; Koie T
    Curr Oncol; 2021 Mar; 28(2):1294-1301. PubMed ID: 33809967
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
    BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
    [TBL] [Abstract][Full Text] [Related]  

  • 68. How to optimize follow-up in patients with a suspicious multiparametric MRI and a subsequent negative targeted prostate biopsy. Results from a large, single-institution series.
    Barletta F; Stabile A; Mazzone E; Brembilla G; Sorce G; Pellegrino F; Scuderi S; Cannoletta D; Cirulli GO; Cucchiara V; Gandaglia G; De Cobelli F; Montorsi F; Briganti A
    Urol Oncol; 2022 Mar; 40(3):103.e17-103.e24. PubMed ID: 34688534
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging.
    Grönberg H; Eklund M; Picker W; Aly M; Jäderling F; Adolfsson J; Landquist M; Haug ES; Ström P; Carlsson S; Nordström T
    Eur Urol; 2018 Dec; 74(6):722-728. PubMed ID: 30001824
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study.
    Rouvière O; Puech P; Renard-Penna R; Claudon M; Roy C; Mège-Lechevallier F; Decaussin-Petrucci M; Dubreuil-Chambardel M; Magaud L; Remontet L; Ruffion A; Colombel M; Crouzet S; Schott AM; Lemaitre L; Rabilloud M; Grenier N;
    Lancet Oncol; 2019 Jan; 20(1):100-109. PubMed ID: 30470502
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
    Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
    Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A Comparison of Cancer Detection Rates Between Template Systematic Biopsies Obtained Using Magnetic Resonance Imaging-Ultrasound Fusion Machine and Freehand Transrectal Ultrasound-Guided Systematic Biopsies.
    Hoge C; Maynor S; Guan T; Naffouje R; Rao M; Verma S; Sidana A
    J Endourol; 2020 Oct; 34(10):1095-1098. PubMed ID: 32631097
    [No Abstract]   [Full Text] [Related]  

  • 73. The oncologic risk of magnetic resonance imaging-targeted and systematic cores in patients treated with radical prostatectomy.
    Gaffney CD; Tin AL; Fainberg J; Fine S; Jibara G; Touijer K; Eastham J; Scardino P; Laudone V; Vickers AJ; Ehdaie B
    Cancer; 2023 Dec; 129(23):3790-3796. PubMed ID: 37584213
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Comparison of Targeted vs Systematic Prostate Biopsy in Men Who Are Biopsy Naive: The Prospective Assessment of Image Registration in the Diagnosis of Prostate Cancer (PAIREDCAP) Study.
    Elkhoury FF; Felker ER; Kwan L; Sisk AE; Delfin M; Natarajan S; Marks LS
    JAMA Surg; 2019 Sep; 154(9):811-818. PubMed ID: 31188412
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Biomarker discrimination and calibration with MRI-targeted biopsies: an analysis with the Stockholm3 test.
    Vigneswaran HT; Palsdottir T; Olsson H; Haug ES; Picker W; Löffeler S; Grönberg H; Eklund M; Nordström T
    Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):457-464. PubMed ID: 33168965
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Why Does Magnetic Resonance Imaging-Targeted Biopsy Miss Clinically Significant Cancer?
    Williams C; Ahdoot M; Daneshvar MA; Hague C; Wilbur AR; Gomella PT; Shih J; Khondakar N; Yerram N; Mehralivand S; Gurram S; Siddiqui M; Pinsky P; Parnes H; Merino M; Wood B; Turkbey B; Pinto PA
    J Urol; 2022 Jan; 207(1):95-107. PubMed ID: 34433302
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies.
    Wegelin O; Exterkate L; van der Leest M; Kummer JA; Vreuls W; de Bruin PC; Bosch JLHR; Barentsz JO; Somford DM; van Melick HHE
    Eur Urol; 2019 Apr; 75(4):582-590. PubMed ID: 30522912
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer.
    Kuru TH; Roethke MC; Seidenader J; Simpfendörfer T; Boxler S; Alammar K; Rieker P; Popeneciu VI; Roth W; Pahernik S; Schlemmer HP; Hohenfellner M; Hadaschik BA
    J Urol; 2013 Oct; 190(4):1380-6. PubMed ID: 23608676
    [TBL] [Abstract][Full Text] [Related]  

  • 79. PI-RADS Version 2.0 Versus Version 2.1: Comparison of Prostate Cancer Gleason Grade Upgrade and Downgrade Rates From MRI-Targeted Biopsy to Radical Prostatectomy.
    Yilmaz EC; Lin Y; Belue MJ; Harmon SA; Phelps TE; Merriman KM; Hazen LA; Garcia C; Johnson L; Lay NS; Toubaji A; Merino MJ; Patel KR; Parnes HL; Law YM; Wood BJ; Gurram S; Choyke PL; Pinto PA; Turkbey B
    AJR Am J Roentgenol; 2024 Jan; 222(1):e2329964. PubMed ID: 37729551
    [No Abstract]   [Full Text] [Related]  

  • 80. The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study.
    Emmett L; Buteau J; Papa N; Moon D; Thompson J; Roberts MJ; Rasiah K; Pattison DA; Yaxley J; Thomas P; Hutton AC; Agrawal S; Amin A; Blazevski A; Chalasani V; Ho B; Nguyen A; Liu V; Lee J; Sheehan-Dare G; Kooner R; Coughlin G; Chan L; Cusick T; Namdarian B; Kapoor J; Alghazo O; Woo HH; Lawrentschuk N; Murphy D; Hofman MS; Stricker P
    Eur Urol; 2021 Dec; 80(6):682-689. PubMed ID: 34465492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.